Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation

Fast, Loren D.; DiLeone, Gilbert; Marschner, Susanne

doi:10.1111/j.1537-2995.2010.02984.x

Cited by 60 publications

(67 citation statements)

References 28 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pathogen-reduction treatment seems to be even more effective than irradiation at abrogating leukocyte immune functions. 60 In general, there is no need for CMV-negative blood products if universal leukodepletion is applied. [61][62][63][64] However, some centers give only CMV-negative blood products for patients undergoing HSCT where both the patient and donor are CMV-negative.…”

Section: Transfusion Therapymentioning

confidence: 99%

Supportive care in severe and very severe aplastic anemia

Höchsmann

Moicean

Risitano

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

for the EBMT Working Party on Aplastic AnemiaOptimal management of aplastic anemia (AA) is not confined to immediate diagnosis, early decision making and timely initiation of major treatment strategies (immunosuppression or SCT) but also involves supportive treatment as a crucial part of patient care. Patients are threatened by complications of cytopenia. Here, we summarize current recommendations for prevention and early treatment of fungal, bacterial and viral infections, transfusion strategy and iron chelation and assess the evidence basis. In fact, many recommendations for patients with AA are not based on randomized studies in AA itself, but they are deduced from other conditions with similar severity of cytopenia. Prevention and treatment of complications like hemorrhage, bacterial and fungal infections and of secondary events like alloimmunization to blood products and iron overload have a significant impact on the prognosis of AA patients and need to be carefully observed in daily practice. More controlled studies on supportive care should be performed in this rare disease.Bone Marrow Transplantation (2013) 48, 168-173; doi:10.1038/bmt.2012.220; published online 3 December 2012Keywords: aplastic anemia; supportive treatment; infection; transfusion; hematopoietic growth factors INTRODUCTION Survival of patients with aplastic anemia (AA) after both immunosuppression and allogeneic BMT improved substantially over the past 30 years. 1 For patients who received immunosuppression, this improvement was not restricted to patients who responded to the specific treatment. 2 Remarkably, the prognosis of non-responders to initial immunosuppression also improved substantially over time. 2 This is most likely due to the impact of supportive treatment on the overall survival of patients. The individual risk of a patient is mainly determined by the neutrophil, and monocyte counts. 2-8 During the past two decades, infection-related mortality and invasive fungal infections decreased. 2 However, infections are still the major threat for patients with severe or very severe AA. In the most recently published large clinical trials in AA, the most prevalent complications and the major causes of death still were bacterial and fungal infections. [3][4][5] In the following sections, we will summarize recommendations on the major aspects of supportive treatment in AA, that is, prophylaxis and early treatment of infections, transfusion strategy and treatment of iron overload.

show abstract

Section: Transfusion Therapymentioning

confidence: 99%

Supportive care in severe and very severe aplastic anemia

Höchsmann

Moicean

Risitano

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…In the case of platelets, these technologies are the Mirasol ® PRT System and Intercept ™ Blood System, which are also effective for T lymphocyte inactivation. 6,7 Literature reviews confirm that pathogen reduction technology methods (Mirasol ® PRT System and Intercept ™ Blood System) have proved effective for leukocyte inactivation in cellular blood components. This implies that pathogen inactivated PCs (with either the Mirasol ® PRT System or Intercept ™ Blood System) are as safe for patients at risk of TA-GvHD as irradiated PCs.…”

Section: Discussionmentioning

confidence: 99%

“…In some countries (France, Spain, Austria, Luxemburg), platelet concentrates (PCs) for high-risk patients are subjected exclusively to pathogen inactivation with the Mirasol ® PRT System or the Intercept ™ Blood System. 6,7 In Poland the Mirasol ® PRT System was introduced in 2009, first for fresh frozen plasma (FFP) then for PCs. The Mirasol ® PRT System is based on exposure to riboflavin (vitamin B2) and UV-light.…”

mentioning

confidence: 99%

Study of CD69 antigen expression and integrity of leukocyte cellular membrane in stored platelet concentrates following irradiation and treatment with Mirasol® PRT System

Lachert¹,

Woźniak²,

Antoniewicz‐Papis³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Leukocytes in transfused blood components, particularly residual lymphocytes, have been shown to contribute to the occurrence of various adverse reactions. One of the most severe is transfusionassociated graft versus host disease (TA-GvHD) following transfusion of blood components contaminated with immunocompetent T lymphocytes. Irradiation is a routine method for protection against TA-GvHD. According to the literature, some pathogen reduction methods have also been proven effective for the inactivation of T lymphocytes, and so they may be considered as an alternative to irradiation.

show abstract

“…UVC irradiation failed to effectively inactivate spores (having a low impact in blood products), West Nile virus and especially HIV (for which screening is performed) [35,36]. Disruption irradiation to prevent transfusion-associated graft versus host disease due to the capacity to inactivate donor leukocytes [13][14][15].…”

Section: Uvc Irradiation Of Pcs and Plasmamentioning

confidence: 99%

Pathogen Reduction Technologies: The Best Solution for Safer Blood?

Picker¹

2013

J Blood Disord Transfus

View full text Add to dashboard Cite

Although it is generally accepted that blood has never been safer than today, transfusion-associated side effects, particularly infective, still occur. Unlike screening strategies, pathogen reduction technologies offer a new approach to increase blood safety by actively/directly targeting possible, also emerging pathogens or donor leukocytes. Advanced technologies for cellular blood products like the psoralen-based INTERCEPT BLOOD SYSTEM or the riboflavin-based Mirasol pathogen reduction technology system have extensively been examined and are on the way to enter the blood bank routine. However, as with any medical treatment, the transfusion of pathogen reduced blood products is not completely risk-free. Due to possible impairment of the treated blood cells the transfusion success is significantly lower as compared to untreated blood products. Long-term side effects concerning the photosensitizers and their photoproducts still remain a matter of debate. This paper outlines current pathogen reduction technologies but also focuses on ethical concerns associated with the employment of these techniques.

show abstract

Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation

Abstract: These in vitro results demonstrate that PRT treatment is more effective than gamma irradiation at abrogating selected WBC immune functions.

Cited by 60 publications

References 28 publications

Supportive care in severe and very severe aplastic anemia

Supportive care in severe and very severe aplastic anemia

Study of CD69 antigen expression and integrity of leukocyte cellular membrane in stored platelet concentrates following irradiation and treatment with Mirasol® PRT System

Pathogen Reduction Technologies: The Best Solution for Safer Blood?

Contact Info

Product

Resources

About